|
gptkbp:instanceOf
|
gptkb:drug
DPP-4 inhibitor
|
|
gptkbp:approvedBy
|
2007
|
|
gptkbp:ATCCode
|
A10BH02
|
|
gptkbp:brand
|
gptkb:Galvus
gptkb:Eucreas
|
|
gptkbp:CASNumber
|
274901-16-5
|
|
gptkbp:combines
|
gptkb:metformin
gptkb:thiazolidinediones
sulfonylureas
|
|
gptkbp:contraindication
|
gptkb:diabetic_ketoacidosis
type 1 diabetes
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:discoveredIn
|
early 2000s
|
|
gptkbp:eliminationHalfLife
|
about 3 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C17H25N3O2
|
|
gptkbp:hasSMILES
|
C1C2CC3CC(C1)CC(C2)(C3)NC(=O)C(C#N)N4CCCC4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
vildagliptin
|
|
gptkbp:IUPACName
|
(S)-1-[N-(3-hydroxy-1-adamantyl)glycyl]pyrrolidine-2-carbonitrile
|
|
gptkbp:KEGGID
|
D08914
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits dipeptidyl peptidase-4
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:proteinBinding
|
9.3%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL429
gptkb:DB04876
6918537
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
hypoglycemia (when combined with sulfonylureas)
|
|
gptkbp:status
|
approved in EU
not approved in US
|
|
gptkbp:UNII
|
20O93L6F9H
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:bfsParent
|
gptkb:Galvus
|
|
gptkbp:bfsLayer
|
5
|